Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults

Emmanuel Maganga, Luke R Smart, Samuel Kalluvya, Johannes B Kataraihya, Ahmed M Saleh, Lama Obeid, Jennifer A Downs, Daniel W Fitzgerald, Robert N Peck, Emmanuel Maganga, Luke R Smart, Samuel Kalluvya, Johannes B Kataraihya, Ahmed M Saleh, Lama Obeid, Jennifer A Downs, Daniel W Fitzgerald, Robert N Peck

Abstract

Introduction: Millions of HIV-infected Africans are living longer due to long-term antiretroviral therapy (ART), yet little is known about glucose metabolism disorders in this group. We aimed to compare the prevalence of glucose metabolism disorders among HIV-infected adults on long-term ART to ART-naïve adults and HIV-negative controls, hypothesizing that the odds of glucose metabolism disorders would be 2-fold greater even after adjusting for possible confounders.

Methods: In this cross-sectional study conducted between October 2012 and April 2013, consecutive adults (>18 years) attending an HIV clinic in Tanzania were enrolled in 3 groups: 153 HIV-negative controls, 151 HIV-infected, ART-naïve, and 150 HIV-infected on ART for ≥ 2 years. The primary outcome was the prevalence of glucose metabolism disorders as determined by oral glucose tolerance testing. We compared glucose metabolism disorder prevalence between each HIV group vs. the control group by Fisher's exact test and used multivariable logistic regression to determine factors associated with glucose metabolism disorders.

Results: HIV-infected adults on ART had a higher prevalence of glucose metabolism disorders (49/150 (32.7%) vs.11/153 (7.2%), p<0.001) and frank diabetes mellitus (27/150 (18.0%) vs. 8/153 (5.2%), p = 0.001) than HIV-negative adults, which remained highly significant even after adjusting for age, gender, adiposity and socioeconomic status (OR = 5.72 (2.78-11.77), p<0.001). Glucose metabolism disorders were significantly associated with higher CD4+ T-cell counts. Awareness of diabetes mellitus was <25%.

Conclusions: HIV-infected adults on long-term ART had 5-fold greater odds of glucose metabolism disorders than HIV-negative controls but were rarely aware of their diagnosis. Intensive glucose metabolism disorder screening and education are needed in HIV clinics in sub-Saharan Africa. Further research should determine how glucose metabolism disorders might be related to immune reconstitution.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. World Health Organization (2013) Global update on HIV treatment 2013: results, impact and opportunities. Geneva, Switzerland: World Health Organization; Available:
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS. Available:
    1. Narayan KMV, Miotti PG, Anand NP, Kline LM, Harmston C, Gulakowski R, et al. HIV and Noncommunicable Disease Comorbidities in the Era of Antiretroviral Therapy: A Vital Agenda for Research in Low- and Middle-Income Country Settings. J Acquir Immune Defic Syndr. 2014;67 Suppl 1: S2–7. 10.1097/QAI.0000000000000267
    1. Awotedu K, Ekpebegh C, Longo-Mbenza B, Iputo J. Prevalence of metabolic syndrome assessed by IDF and NCEP ATP 111 criteria and determinants of insulin resistance among HIV patients in the Eastern Cape Province of South Africa. Diabetes Metab Syndr Clin Res Rev. 2010;4: 210–214. 10.1016/j.dsx.2010.09.002
    1. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M, et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J. 2012;13: 43
    1. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009;14: 371–80.
    1. Petersen M, Yiannoutsos CT, Justice A, Egger M. Observational Research on NCDs in HIV-Positive Populations: Conceptual and Methodological Considerations. J Acquir Immune Defic Syndr. 2014;67 Suppl 1: S8–S16. 10.1097/QAI.0000000000000253
    1. Ali MK, Magee MJ, Dave JA, Ofotokun I, Tungsiripat M, Jones TK, et al. HIV and Metabolic, Body, and Bone Disorders: What We Know From Low- and Middle-Income Countries. J Acquir Immune Defic Syndr. 2014;67 Suppl 1: S27–39. 10.1097/QAI.0000000000000256
    1. Tanzania Commission for AIDS (2013) Tanzania HIV/AIDS and Malaria Indicator Survey 2011–12. Dar es Salaam, Tanzania: Tanzanian Ministry of Health.
    1. National AIDS Control Programme (NACP) (2009) National Guidelines for the Management of HIV/AIDS, 3rd edition Dar es Salaam, Tanzania: Tanzanian Ministry of Health.
    1. World Health Organization (2011) WHO STEPS Instrument. Geneva, Switzerland: World Health Organization.
    1. World Health Organization (2011) WHO STEPS Instrument. Geneva, Switzerland: World Health Organization; Available: h
    1. Priya M, Mohan Anjana R, Pradeepa R, Jayashri R, Deepa M, Bhansali A, et al. Comparison of capillary whole blood versus venous plasma glucose estimations in screening for diabetes mellitus in epidemiological studies in developing countries. Diabetes Technol Ther. 2011;13: 586–91. 10.1089/dia.2010.0218
    1. Goff LM, Frost GS, Hamilton G, Thomas EL, Dhillo WS, Dornhorst A, et al. Carbohydrate-induced manipulation of insulin sensitivity independently of intramyocellular lipids. Br J Nutr. 2003;89: 365–75. 10.1079/BJN2002789
    1. Chobanian AA V, Bakris GL, Black HR, Cushman WC, Green L a, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42: 1–104.
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1: S81–90. 10.2337/dc14-S081
    1. International Diabetes Federation. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23: 579–93. 10.1111/j.1464-5491.2006.01918.x
    1. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007;45: 426–31. 10.1097/QAI.0b013e318074ef83
    1. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165: 1179–84. 10.1001/archinte.165.10.1179
    1. Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42: 1754–71. 10.1093/ije/dyt198
    1. Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, et al. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013;12: 1–9.
    1. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19: 1375–83.
    1. Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57: 284–9. 10.1097/QAI.0b013e318221863f
    1. Manuthu EM, Joshi MD, Lule GN, Karari E. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr Med J. 2008;85: 10–7.
    1. Mercier S, Gueye NFN, Cournil A, Fontbonne AA, Copin N, Ndiaye I, et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr. 2009;51: 224–30. 10.1097/QAI.0b013e31819c16f4
    1. Ngatchou W, Lemogoum D, Ndobo P, Tiogou E, Nga E, Kouanfack C, et al. Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. Vasc Health Risk Manag. 2013;9: 509–16. 10.2147/VHRM.S42350
    1. Thompson V, Medard B, Taseera K, Chakera AJ, Andia I, Emenyonu N, et al. Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara, Uganda. AIDS Res Hum Retroviruses. 2011;27: 785–91. 10.1089/AID.2010.0272
    1. Hattingh Z, Walsh C. The metabolic profiles of HIV-infected and non-infected women in Mangaung, South Africa. South African J Clin Nutr. 2009;22: 23–28.
    1. Mbanya JCN, Motala A a, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-Saharan Africa. Lancet. Elsevier Ltd; 2010;375: 2254–66.
    1. Msyamboza KP, Mvula CJ, Kathyola D. Prevalence and correlates of diabetes mellitus in Malawi: population-based national NCD STEPS survey. BMC Endocr Disord. 2014;14: 41 10.1186/1472-6823-14-41
    1. Peck R, Mghamba J, Vanobberghen F, Kavishe B, Rugarabamu V, Smeeth L, et al. Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: a cross-sectional survey. Lancet Glob Heal. Elsevier Ltd; 2014; 1–8. 10.1016/S2214-109X(14)70033-6
    1. Peck R, Fitzgerald DW, Liautaud B, Deschamps MM, Verdier RI, Beaulieu ME, et al. The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985–2000. J Acquir Immune Defic Syndr. 2003;33: 470–5.
    1. Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS. 2011;22: 43–5. 10.1258/ijsa.2010.010256
    1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353: 2093–9.
    1. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, et al. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS. 2014;28: 1451–61. 10.1097/QAD.0000000000000266
    1. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, et al. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014;65: 167–74. 10.1097/01.qai.0000437171.00504.41

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit